Physician profile
Alidad M Zadeh
NPI 1013154400
$11,667.12
in general payments reported to CMS, 2019-2025
62 companies · $739 in 2025
The $739 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,325 · 2020: $1,746 · 2021: $2,083 · 2022: $1,299 · 2023: $1,151 · 2024: $2,324 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,214.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,643.88 | 2019-2025 | Mavyret, Linzess, Viberzi |
| Novo Nordisk INC | $1,086.97 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $952.49 | 2019-2025 | Airsupra, Farxiga |
| Corcept Therapeutics | $790.78 | 2019-2024 | Korlym |
| Amgen INC. | $771.46 | 2019-2025 | Tezspire, Prolia, Evenity |
| Merck Sharp & Dohme LLC | $639.08 | 2019-2025 | Verquvo, Belsomra, Delstrigo |
| Lilly USA, LLC | $380.17 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $372.76 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $340.24 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $339.68 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $338.04 | 2019-2024 | Xarelto, Spravato |
| Allergan, INC. | $329.56 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $315.08 | 2019-2024 | Lifevest |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $313.31 | 2019-2024 | Xifaxan, Trulance |
| Boston Scientific Corporation | $264.24 | 2021-2022 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alidad Zadeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.